1. Home
  2. PSBD vs PRTC Comparison

PSBD vs PRTC Comparison

Compare PSBD & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PSBD

Palmer Square Capital BDC Inc.

HOLD

Current Price

$12.01

Market Cap

386.6M

Sector

N/A

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$17.60

Market Cap

386.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSBD
PRTC
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
386.6M
386.7M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
PSBD
PRTC
Price
$12.01
$17.60
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$13.30
N/A
AVG Volume (30 Days)
140.7K
1.8K
Earning Date
02-26-2026
08-28-2025
Dividend Yield
13.78%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
N/A
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.22
Revenue Growth
N/A
1265.60
52 Week Low
$11.51
$13.30
52 Week High
$16.16
$20.00

Technical Indicators

Market Signals
Indicator
PSBD
PRTC
Relative Strength Index (RSI) 46.90 57.65
Support Level $11.86 $16.65
Resistance Level $12.28 $17.70
Average True Range (ATR) 0.23 0.38
MACD -0.00 0.10
Stochastic Oscillator 44.34 82.27

Price Performance

Historical Comparison
PSBD
PRTC

About PSBD Palmer Square Capital BDC Inc.

Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: